• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Adagene Inc.

    2/4/25 12:26:11 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Adagene Inc.

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    005329107

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    Smith Vincent C
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    523,105.00
    6Shared Voting Power

    3,310,701.00
    7Sole Dispositive Power

    523,105.00
    8Shared Dispositive Power

    3,310,701.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,833,806.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.9 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) Includes sole voting and dispositive power over 523,105 Ordinary Shares held directly, and shared voting and dispositive power over 3,125,000 Ordinary Shares held by Red Beard Holdings, LLC and 185,701 Ordinary Shares held by VCS Master Holdings GP. Mr. Smith is the Manager of Red Beard Holdings, LLC therefore may be deemed to have beneficial ownership of the shares held thereby. Mr. Smith is the grantor of all of the trusts that are partners of VCS Master Holdings GP and disclaims beneficial ownership of the shares held thereby. (2) Represents Ordinary Shares held by the Reporting Person. There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 005329 107 has been assigned to the ADSs of the Issuer, which are quoted on NASDAQ Stock Market under the symbol "ADAG." Each ADS represents one and one quarter Ordinary Share.


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    Red Beard Holdings, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,125,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,125,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,125,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Mr. Smith is the Manager of Red Beard Holdings, LLC, and may be deemed to have beneficial ownership of the shares held thereby. (2) Represents the ordinary shares, par value $0.0001 per share of the Issuer ("Ordinary Shares") held by the Reporting Person. There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 005329 107 has been assigned to the American depositary shares ("ADSs") of the Issuer, which are quoted on NASDAQ Stock Market under the symbol "ADAG." Each ADS represents one and one quarter Ordinary Share.


    SCHEDULE 13G

    CUSIP No.
    005329107


    1Names of Reporting Persons

    VCS Master Holdings GP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    185,701.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    185,701.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    185,701.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.0 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) Mr. Smith is the grantor of all of the trusts that are partners of VCS Master Holdings GP, and disclaims beneficial ownership of the shares held thereby. (2) Represents Ordinary Shares held by the Reporting Person. There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 005329 107 has been assigned to the ADSs of the Issuer, which are quoted on NASDAQ Stock Market under the symbol "ADAG." Each ADS represents one and one quarter Ordinary Share.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Adagene Inc.
    (b)Address of issuer's principal executive offices:

    4F, BUILDING C14, NO. 218, XINGHU STREET, SUZHOU INDUSTRIAL PARK, JIANGSU, CHINA, 00000.
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of each of the following: (i) Red Beard Holdings, LLC, a limited liability company organized under the laws of Delaware ("Red Beard"); (ii) VCS Master Holdings GP, a Delaware General Partnership ("VCS"); and (iii) Vincent C. Smith, an individual ("Mr. Smith", and together with Red Beard and VCS, the "Reporting Persons"). Mr. Smith is the Manager of Red Beard Holdings, and therefore may be deemed to have beneficial ownership of the shares reported herein. Mr Smith is the grantor of all the trusts that are the partners of VCS, and disclaims beneficial ownership of the shares held thereby.
    (b)Address or principal business office or, if none, residence:

    The mailing address for each of the Reporting Persons is 17595 Harvard Avenue, Suite C511, Irvine, California 92614.
    (c)Citizenship:

    (i) Red Beard is a limited liability company organized under the laws of Delaware; (ii) VCS is a general partnership organized under the laws of Delaware; and (iii) Mr. Smith is a citizen of the United States of America.
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    005329107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Red Beard beneficially owns an aggregate of 3,125,000 Ordinary Shares; (ii) VCS beneficially owns an aggregate of 185,701 Ordinary Shares; and (iii) Mr. Smith may be deemed to beneficially own an aggregate of 3,833,806 Ordinary Shares, including 523,105 Ordinary Shares held directly, 3,125,000 Ordinary Shares held by Red Beard and 185,701 Ordinary Shares held by VCS.
    (b)Percent of class:

    The percentage of shares beneficially owned by the Reporting Persons below is based upon 55,338,480 of the Issuer's Ordinary Shares outstanding as of June 30, 2024, as set forth in Exhibit 99.2 to the Issuer's Current Report on Form 6-K filed with the Securities and Exchange Commission on November 7, 2024:
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Red Beard: 0 VCS: 0 Mr. Smith: 523,105

     (ii) Shared power to vote or to direct the vote:

    Red Beard: 3,125,000 VCS: 185,701 Mr. Smith: 3,310,701

     (iii) Sole power to dispose or to direct the disposition of:

    Red Beard: 0 VCS: 0 Mr. Smith: 523,105

     (iv) Shared power to dispose or to direct the disposition of:

    Red Beard: 3,125,000 VCS: 185,701 Mr. Smith: 3,310,701

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Smith Vincent C
     
    Signature:Vincent C. Smith
    Name/Title:Individual
    Date:02/04/2025
     
    Red Beard Holdings, LLC
     
    Signature:Vincent C. Smith
    Name/Title:Manager
    Date:02/04/2025
     
    VCS Master Holdings GP
     
    Signature:Jerry Rickmeyer
    Name/Title:Trustee & Partner
    Date:02/04/2025
    Get the next $ADAG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAG

    DatePrice TargetRatingAnalyst
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    2/1/2022$27.00 → $15.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

      CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for over forty weeks Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months and only 1 out of 41 patients was censored due to early withdrawal within the first 12 months SAN DIEGO and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company

      5/22/25 5:05:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

      - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

      4/28/25 8:00:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

      SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3. Abstract Title: Safety and Efficacy of ADG126 (an Anti-CTLA-4 Masking Antibody) in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRCDate: Saturday, May 31, 2025Poster Viewing: 9:00 AM-12:00 PM CDTOnsite Location: McCormick Place, Chicago, IL, Board #248Abstract Number: 3579 Poster will be made available on the Publications page of the company's website here. About AdageneAdagene

      4/23/25 10:05:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Leadership Updates

    Live Leadership Updates

    See more
    • Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

      - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

      4/28/25 8:00:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

      - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a

      3/7/24 4:01:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

      - Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene's novel anti-CTLA-4 therapies delivered systemically at higher and repeated doses with compelling safety - SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) --  Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board (the "SAB"). Professor Marabelle is a physician-scientist with expertise in oncology and imm

      3/5/23 7:39:30 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    SEC Filings

    See more
    • Amendment: SEC Form F-3/A filed by Adagene Inc.

      F-3/A - Adagene Inc. (0001818838) (Filer)

      5/23/25 4:06:11 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Adagene Inc.

      6-K - Adagene Inc. (0001818838) (Filer)

      5/22/25 5:05:23 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

      SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)

      5/15/25 5:29:08 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adagene downgraded by Morgan Stanley

      Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

      1/31/25 8:29:36 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Adagene with a new price target

      Morgan Stanley reiterated coverage of Adagene with a rating of Overweight and set a new price target of $15.00 from $27.00 previously

      2/1/22 9:41:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adagene Inc.

      SC 13G/A - Adagene Inc. (0001818838) (Subject)

      11/7/24 4:32:13 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adagene Inc. (Amendment)

      SC 13D/A - Adagene Inc. (0001818838) (Subject)

      3/1/24 4:30:20 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Adagene Inc. (Amendment)

      SC 13G/A - Adagene Inc. (0001818838) (Subject)

      2/9/24 8:35:54 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Financials

    Live finance-specific insights

    See more
    • Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

      – Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of

      8/30/22 5:25:00 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care